Related Experiment Video
Updated: Jan 29, 2026

Subcutaneous Neurotrophin 4 Infusion Using Osmotic Pumps or Direct Muscular Injection Enhances Aging Rat Laryngeal Muscles
Published on: June 13, 2017
Neurotrophins and their involvement in digestive cancers
Sabrina Blondy1, Niki Christou1,2, Valentin David1,3
1Laboratoire EA3842 CAPTuR « Contrôle de l'Activation cellulaire, Progression Tumorale et Résistance thérapeutique″, Université de Limoges, Faculté de médecine, 2 Rue du docteur Marcland, 87025, Limoges, France.
Abstract:
Cancers of the digestive system, including esophageal, gastric, pancreatic, hepatic, and colorectal cancers, have a high incidence and mortality worldwide. Efficient therapies have improved patient care; however, many challenges remain including late diagnosis, disease recurrence, and resistance to therapies. Mechanisms responsible for these aforementioned challenges are numerous. This review focuses on neurotrophins, including NGF, BDNF, and NT3, and their specific tyrosine kinase receptors called tropomyosin receptor kinase (Trk A, B, C, respectively), associated with sortilin and the p75 neurotrophin receptor (p75NTR), and their implication in digestive cancers. Globally, p75NTR is a frequently downregulated tumor suppressor. On the contrary, Trk and their ligands are considered oncogenic factors. New therapies which target NT and/or their receptors, or use them as diagnosis biomarkers could help us to combat digestive cancers.
Insights
Neurotrophins and their receptors are implicated in digestive cancers. Targeting these pathways or using them as biomarkers may offer new therapeutic strategies for esophageal, gastric, and colorectal cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Digestive system cancers (esophageal, gastric, pancreatic, hepatic, colorectal) exhibit high global incidence and mortality.
- Despite therapeutic advancements, challenges like late diagnosis, recurrence, and treatment resistance persist.
- The underlying mechanisms for these challenges are complex and multifactorial.
Purpose of the Study:
- To review the role of neurotrophins (NGF, BDNF, NT3) and their receptors (Trk A, B, C; p75NTR) in digestive cancers.
- To elucidate the oncogenic and tumor-suppressive functions of these neurotrophin signaling pathways.
- To explore potential therapeutic and diagnostic applications targeting neurotrophin signaling in digestive malignancies.
Main Methods:
- Literature review focusing on neurotrophin signaling pathways in digestive cancers.
- Analysis of the expression and function of neurotrophins (NGF, BDNF, NT3) and their receptors (Trk, p75NTR).
- Examination of the association between neurotrophin signaling and clinical outcomes, including diagnosis, recurrence, and therapy resistance.
Main Results:
- Neurotrophin receptor (Trk) signaling and their ligands are frequently implicated as oncogenic factors in digestive cancers.
- The p75 neurotrophin receptor (p75NTR) often functions as a downregulated tumor suppressor.
- Dysregulation of neurotrophin pathways contributes to challenges in cancer management.
Conclusions:
- Neurotrophin signaling pathways play a significant role in the development and progression of digestive cancers.
- Targeting neurotrophin receptors or ligands presents a promising avenue for novel cancer therapies.
- Neurotrophins and their receptors may serve as valuable biomarkers for early diagnosis and prognosis in digestive cancers.
Related Concept Videos
Carbohydrate Digestion
What is Monogastric Digestion?
Lipid Digestion
Protein Digestion
Regulation of the Digestive System
The effectors in this regulation system are glands and smooth muscles. Activation of...
Other Disorders of Digestive System

